Drug Res (Stuttg) 2013; 63(10): 545-549
DOI: 10.1055/s-0033-1348223
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

Comparative Bioequivalence Study of Two Marketed Formulation of Betamethasone Injectable Suspensions

P. Zakeri-Milani
1   Liver and Gastrointestinal Diseases Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
S. Ghanbarzadeh
2   Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
S. Basmenji
3   Dana Pharmaceutical Company, Tabriz, Iran
H. Valizadeh
4   Research Center for Pharmaceutical Nanotechnology and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran
› Author Affiliations
Further Information

Publication History

received 21 April 2013

accepted 18 May 2013

Publication Date:
18 June 2013 (online)



The aim of this study was to determine the bioequivalence of generic (test) and branded (reference) formulations of betamethasone injectable suspension in healthy Iranian subjects for the purpose of meeting regulatory requirements for bioequivalence of the generic formulation in Iran.


24 healthy Iranian male volunteers were participated for this single-dose, randomized, open label, 2 period crossover study separated by a 2-week washout period. For the assessment of betamethasone, blood samples were obtained before and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 h after drug administration. Plasma concentration of betamethasone was analyzed with a simple, rapid and validated high performance liquid chromatography method with ultraviolet detection. Pharmacokinetic parameters, representing the rate (Cmax, Tmax), and the extent (AUC0–t and AUC0–∞) of betamethasone absorption were calculated and analyzed for 2 formulations. The 2 formulations were to be considered bioequivalent if the 90% confidence intervals (CI)s for the logarithm-transformed values of Cmax, AUC0–t and AUC0–∞ fell within the predetermined range of 80–125%.


The 90% CIs of Cmax, AUC0–t and AUC0–∞ were 85.4–104.4%, 96.2–112.1% and 98.3–115.8%, respectively.


Based on the 90% CIs of Cmax, AUC0–t and AUC0–∞ in these healthy Iranian male subjects, the test and reference formulations of betamethasone injectable suspension met the regulatory requirements for bioequivalence.

  • References

  • 1 Dalziel SR, Rea HH, Walker NK et al. Long term effects of antenatal betamethasone on lung function: 30 Year follow up of a randomised controlled trial. Thorax 2006; 61: 678-683
  • 2 Fenton C, Plosker GL. Calcipotriol/betamethasone dipropionate: A review of its use in the treatment of psoriasis vulgaris. Am J Clin Dermatol 2004; 5: 463-478
  • 3 He C, Fan H, Tan J et al. Pharmacokinetics of betamethasone and betamethasone 17-monopropionate in Chinese healthy volunteers after intramuscular injection of betamethasone phosphate/betamethasone dipropionate. Arzneim.-Forsch 2010; 61: 417-420
  • 4 Kaufmann R, Bibby AJ, Bissonnette R et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002; 205: 389-393
  • 5 Marinoni E, Zacharopoulou C, Di Rocco A et al. Effect of Betamethasone In Vivo on Placental Adrenomedullin in Human Pregnancy. J Soc Gynecol Investig 2006; 13: 418-424
  • 6 Moss TJM, Doherty DA, Nitsos I et al. Pharmacokinetics of betamethasone after maternal or fetal intramuscular administration. Am J Obstet Gynecol 2003; 189: 1751-1757
  • 7 Salem II, Najib NM. Pharmacokinetics of Betamethasone After Single-Dose Intramuscular Administration of Betamethasone Phosphate and Betamethasone Acetate to Healthy Subjects. Clin Ther 2012; 34: 214-220
  • 8 Scadding GK. Other anti-inflammatory uses of intranasal corticosteroids in upper respiratory inflammatory diseases. Eur J Allergy Clin Immunol Supplement 2000; 55: 19-23
  • 9 Shou M, Galinada WA, Wei YC et al. Development and validation of a stability-indicating HPLC method for simultaneous determination of salicylic acid, betamethasone dipropionate and their related compounds in Diprosalic Lotion. J Pharm Biomed Anal 2009; 50: 356-361
  • 10 Snyman JR, Potter PC, Groenewald M et al. Effect of betamethasone-loratadine combination therapy on severe exacerbations of allergic rhinitis: A randomised, controlled trial. Clin Drug Investig 2004; 24: 265-274
  • 11 Zakeri-Milani P, Barzegar-Jalali M, Tajerzadeh H et al. Simultaneous determination of naproxen, ketoprofen and phenol red in samples from rat intestinal permeability studies: HPLC method development and validation. J Pharm Biomed Anal 2005; 39: 624-630
  • 12 Zakeri-Milani P, Nemati M, Ghanbarzadeh S et al. Fasted state bioavailability of two delayed release formulations of divalproex sodium in healthy Iranian volunteers. Arzneim.-Forsch 2011; 61: 439-443
  • 13 Zakeri-Milani P, Valizadeh H, Ghanbarzadeh S et al. Pharmacokinetics and comparative bioavailability study of two clarithromycin suspensions following administration of a single oral dose to healthy volunteers. Arzneim.-Forsch 2009; 59: 429-432
  • 14 Petersen MC, Nation RL, Ashley JJ. Simultaneous determination of betamethasone, betamethasone acetate and hydrocortisone in biological fluids using high-performance liquid chromatography. J Chrom B Biomed Sci Appl 1980; 183: 131-139
  • 15 Cheng WS, Chen JL, Chiang CH. Simultaneous determination of plasma betamethasone disodium phosphate and betamethasone in rabbit by high performance liquid chromatography. J Food Drug Anal 2009; 17: 348-356
  • 16 Fu Q, Shou M, Chien D et al. Development and validation of a stability-indicating RP-HPLC method for assay of betamethasone and estimation of its related compounds. J Pharm Biomed Anal 2011; 51: 617-625
  • 17 Valizadeh H, Nemati M, Hallaj-Nezhadi S et al. Single dose bioequivalence study of alpha methyldopa tablet formulations using a modified HPLC method. Arzneim.-Forsch 2010; 60: 607-611
  • 18 Zakeri-Milani P, Ghanbarzadeh S, Valizadeh H. Comparative in vitro Dissolution and in vivo Bioequivalence of 2 Pentoxifylline Sustained Release Formulations. Arzneim.-Forsch 2012; 62: 335-339
  • 19 Zakeri-Milani P, Valizadeh H, Islambulchilar Z. Comparative bioavailability study of two cefixime formulations administered orally in healthy male volunteers. Arzneim.-Forsch 2008; 58: 97-100
  • 20 Vybiralova Z, Nobilis M, Zoulova J et al. High-performance liquid chromatographic determination of ciprofloxacin in plasma samples. J Pharm Biomed Anal 2005; 37: 851-858
  • 21 Arthur KE, Wolff JC, Carrier DJ. Analysis of betamethasone, dexamethasone and related compounds by liquid chromatography/electrospray mass spectrometry. Rapid Commun Mass Spectrom 2004; 18: 678-684
  • 22 Chocholous P, Salabová M, Solich P. Simple determination of betamethasone and chloramphenicol in a pharmaceutical preparation using a short monolithic column coupled to a sequential injection system. J Sep Sci 2006; 29: 2494-2499
  • 23 Deng P, Chen XY, Dai XJ et al. Liquid chromatography/tandem mass spectrometry in determination of betamethasone concentration in rabbit plasma. Acad J Second Mil Med Univ 2008; 29: 326-330
  • 24 Narayana B, Veena K. A new analytical system for the spectrophotometric determination of betamethasone. Oxid Commun 2010; 34: 379-384
  • 25 Qu TT, Zhang R, Wang BJ et al. Determination of betamethasone in human plasma by liquid chromatography with tandem mass. Yaoxue Xuebao 2008; 43: 402-407
  • 26 Teixeira L, Mundim I, Souza W et al. An LC-MS/MS-ESI method for the quantification of betamethasone in bioequivalence studies. Acta Chromatographica 2010; 23: 415-428
  • 27 Wulandari L, Indrayanto G. HPTLC determination of betamethasone in tablets and its validation. J Liq Chromatogr Related Technol 2003; 26: 2709-2717
  • 28 Salem II, Alkhatib M, Najib N. LC/MS/MS determination of betamethasone and its phosphate and acetate esters in human plasma after sample stabilization. J Pharm Biomed Anal 2011; 56: 983-991
  • 29 Petersen MC, Ashley JJ, McBride WG et al. Disposition of betamethasone in parturient women after intramuscular administration. Br J Clin Pharmacol 1984; 18: 383-392